Ligand id: 7692

Name: pidilizumab

Compound class Antibody
International Nonproprietary Names
INN number INN
9689 pidilizumab
BAT mAb | CT-011 | MDV9300
Database Links
Specialist databases
IMGT/mAb-DB 453
Other databases
GtoPdb PubChem SID 223366026
Search PubMed clinical trials pidilizumab
Search PubMed titles pidilizumab
Search PubMed titles/abstracts pidilizumab
Wikipedia Pidilizumab
Pidilizumab was developed with the intention of targeting the lymphocytic programmed death receptor-1 (PD-1) immune checkpoint. It is a humanized antibody derived from the murine BAT-1 monoclonal [6]. However, the originators (Medivation, licensed from CureTECH) have disclosed that the main mechanism of action of pidilizumab is not PD-1 blockade> The CureTECH website states that the primary molecular target is in fact the NOTCH ligand Delta-like 1 (DLL1). They go on to identify hypoglycosylated/nonglycosylated forms of PD-1, that are found on a distinct subpopulation of exhausted T cells, as secondary pidilizumab binding partners. Pidilizumab is an IgG1 isotype which suggests potent ADCC (antibody-dependent cell-mediated cytotoxicity) activity, which may or may not explain its clinical effect. This is in contrast to many of the other anti-PD-1 and anti PD-L1 mAbs which are IgG4 with much weaker effector activity, or that have been engineered to exhibit decreased FcR binding. This revelation around pidilizumab's MOA is discussed further in the 'In the Pipeline' blog post Medivation Decides That Their Drug Isn't What They Thought.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.